SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-072192
Filing Date
2023-12-21
Accepted
2023-12-21 16:02:16
Documents
13
Period of Report
2023-12-15
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-20231215.htm   iXBRL 8-K 42976
2 EX-3.1 rare-ex3_1.htm EX-3.1 113024
  Complete submission text file 0000950170-23-072192.txt   292788

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rare-20231215_lab.xml EX-101.LAB 13343
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rare-20231215.xsd EX-101.SCH 2475
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rare-20231215_pre.xml EX-101.PRE 9844
7 EXTRACTED XBRL INSTANCE DOCUMENT rare-20231215_htm.xml XML 4697
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 231505266
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)